These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 11891480

  • 1. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
    Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH.
    Nucl Med Commun; 2002 Mar; 23(3):229-36. PubMed ID: 11891480
    [Abstract] [Full Text] [Related]

  • 2. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G, Boerman O.
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [Abstract] [Full Text] [Related]

  • 3. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.
    J Clin Oncol; 2005 Sep 20; 23(27):6540-8. PubMed ID: 16170161
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W.
    Cancer Biother Radiopharm; 2004 Aug 20; 19(4):466-77. PubMed ID: 15453961
    [Abstract] [Full Text] [Related]

  • 5. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E.
    J Clin Oncol; 1997 Apr 20; 15(4):1529-37. PubMed ID: 9193349
    [Abstract] [Full Text] [Related]

  • 6. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM.
    J Clin Oncol; 2003 Nov 01; 21(21):3995-4000. PubMed ID: 14581422
    [Abstract] [Full Text] [Related]

  • 7. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [Abstract] [Full Text] [Related]

  • 8. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.
    J Nucl Med; 1999 Jun 01; 40(6):986-92. PubMed ID: 10452315
    [Abstract] [Full Text] [Related]

  • 9. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O'Keefe G, Papenfuss AT, Bolton DM, Davis ID, Scott AM.
    Urol Oncol; 2011 Jun 01; 29(4):411-20. PubMed ID: 19523858
    [Abstract] [Full Text] [Related]

  • 10. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH, Shen CT, Xue YL, Qiu ZL, Luo QY.
    Hell J Nucl Med; 2013 Jun 01; 16(3):199-203. PubMed ID: 24251307
    [Abstract] [Full Text] [Related]

  • 11. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V, Jain AL, Eluvathingal TJ, Sidana A.
    Curr Urol Rep; 2019 Aug 29; 20(10):56. PubMed ID: 31468240
    [Abstract] [Full Text] [Related]

  • 12. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D'Ambrosio D, Bernardo A, Brunocilla E, Schiavina R, Maffione AM, Chondrogiannis S, Grassetto G, Colletti PM, Rubello D, Fanti S, Trifirò G.
    Clin Nucl Med; 2014 Jun 29; 39(6):e320-4. PubMed ID: 24566409
    [Abstract] [Full Text] [Related]

  • 13. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
    Minamimoto R, Nakaigawa N, Nagashima Y, Toyohara J, Ueno D, Namura K, Nakajima K, Yao M, Kubota K.
    Abdom Radiol (NY); 2016 Mar 29; 41(3):521-30. PubMed ID: 27039323
    [Abstract] [Full Text] [Related]

  • 14. Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
    Hsu CH, Liu RS, Wu CH, Chen SM, Shih LS.
    J Formos Med Assoc; 2002 Jul 29; 101(7):459-67. PubMed ID: 12353337
    [Abstract] [Full Text] [Related]

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul 29; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 16. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T, Ozülker F, Ozbek E, Ozpaçaci T.
    Nucl Med Commun; 2011 Apr 29; 32(4):265-72. PubMed ID: 21301376
    [Abstract] [Full Text] [Related]

  • 17. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J.
    Eur J Nucl Med Mol Imaging; 2004 Apr 29; 31(4):491-8. PubMed ID: 14666387
    [Abstract] [Full Text] [Related]

  • 18. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
    Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P.
    Lancet Oncol; 2007 Apr 29; 8(4):304-10. PubMed ID: 17395103
    [Abstract] [Full Text] [Related]

  • 19. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ.
    Thyroid; 2001 Dec 29; 11(12):1169-75. PubMed ID: 12186505
    [Abstract] [Full Text] [Related]

  • 20. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I, Can C.
    Acta Radiol; 2005 Dec 29; 46(8):895-9. PubMed ID: 16392617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.